Epigenetic modulation of PTEN expression during antiandrogenic therapies in human prostate cancer.

Although the tumor-suppressor phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is frequently mutated or deleted in a wide variety of solid tumors, some malignancies, including prostate cancer, exhibit undetectable PTEN protein without loss of PTEN gene. Aim of this study was to evaluate whether the PTEN downmodulation, observed during bicalutamide treatment, was due to epigentic events. We analyzed the expression of PTEN in presence or absence of azacitidine or valproic acid in a panel of 50 primary cultures derived from naive (UNT, 23 ptz) and bicalutamide-based neoadjuvant hormone therapy-treated patients (NHT, 27 pts). Results showed that Western blot and PCR analyses showed that 54 and 68% of primary cultures displayed detectable amounts of PTEN protein and mRNA, respectively. Treatment with azacitidine increased the percentage of PTEN-positive cultures up to 72 and 80% for PTEN protein and mRNA determination, respectively. Treatment with valproic acid was able to increase the percentage of PTEN-positive cultures up to 80 and 74% for PTEN protein and mRNA determination, respectively. The percentage of cultures with undetectable levels of PTEN protein was significatively higher in cultures derived NHT patients respect to cultures derived from UNT men (P=0.020). Valproic acid reduced significantly the percentage of cultures PTEN-negative only at protein level and only in NHT (P=0.029) group. In conclusion, our data suggests that antiandrogenic therapy reduced PTEN expression by epigenetic mechanisms suggesting that epigenetic drugs, upmodulating PTEN expression, can reduce Akt activity and probably enhance the efficacy of antiandrogenic therapy.

[1]  P. Abel,et al.  Predictive value of PTEN and AR coexpression of sustained responsiveness to hormonal therapy in prostate cancer--a pilot study. , 2008, Neoplasia.

[2]  A. Angelucci,et al.  Effects of dutasteride on prostate carcinoma primary cultures: a comparative study with finasteride and MK386. , 2008, The Journal of urology.

[3]  C. Vicentini,et al.  Akt down‐modulation induces apoptosis of human prostate cancer cells and synergizes with EGFR tyrosine kinase inhibitors , 2008, The Prostate.

[4]  C. Vicentini,et al.  Gefitinib and bicalutamide show synergistic effects in primary cultures of prostate cancer derived from androgen-dependent naive patients. , 2007, Oncology reports.

[5]  R. Vessella,et al.  Bicalutamide increases phospho-Akt levels through Her2 in patients with prostate cancer. , 2007, Endocrine-related cancer.

[6]  J. Kreisberg,et al.  Cross-talk between the androgen receptor and the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer. , 2007, Current cancer drug targets.

[7]  Shunyou Wang,et al.  Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development. , 2007, Cancer research.

[8]  D. Troyer,et al.  Determining Risk of Biochemical Recurrence in Prostate Cancer by Immunohistochemical Detection of PTEN Expression and Akt Activation , 2007, Clinical Cancer Research.

[9]  Xiuli Wang,et al.  Histone deacetylase inhibitor trichostatin a potentiates doxorubicin‐induced apoptosis by up‐regulating PTEN expression , 2007, Cancer.

[10]  Daniel J. Freeman,et al.  Genetic background controls tumor development in PTEN-deficient mice. , 2006, Cancer research.

[11]  M. Gleave,et al.  Loss of PTEN is associated with progression to androgen independence , 2006, The Prostate.

[12]  S. Morrison,et al.  Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells , 2006, Nature.

[13]  H. Stoop,et al.  The PTEN gene in locally progressive prostate cancer is preferentially inactivated by bi‐allelic gene deletion , 2006, The Journal of pathology.

[14]  L. Martínez-Piñeiro,et al.  Molecular biology in prostate cancer , 2006, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

[15]  A. Angelucci,et al.  Retracted: Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitro , 2005, International journal of cancer.

[16]  T. H. van der Kwast,et al.  Targeted biallelic inactivation of Pten in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis. , 2005, Cancer research.

[17]  A. Angelucci,et al.  Epithelial and prostatic marker expression in short-term primary cultures of human prostate tissue samples. , 2005, International journal of oncology.

[18]  P. Scardino,et al.  High Levels of Phosphorylated Form of Akt-1 in Prostate Cancer and Non-Neoplastic Prostate Tissues Are Strong Predictors of Biochemical Recurrence , 2004, Clinical Cancer Research.

[19]  J. Isaacs,et al.  Enhanced Redundancy in Akt and Mitogen-activated Protein Kinase-induced Survival of Malignant versus Normal Prostate Epithelial Cells , 2004, Cancer Research.

[20]  P Roy-Burman,et al.  Genetically defined mouse models that mimic natural aspects of human prostate cancer development. , 2004, Endocrine-related cancer.

[21]  J. Veltman,et al.  Loss of a small region around the PTEN locus is a major chromosome 10 alteration in prostate cancer xenografts and cell lines , 2004, Genes, chromosomes & cancer.

[22]  D. Leroith,et al.  PTEN inhibits cell proliferation and induces apoptosis by downregulating cell surface IGF-IR expression in prostate cancer cells , 2004, Oncogene.

[23]  P. Pandolfi,et al.  Pten Dose Dictates Cancer Progression in the Prostate , 2003, PLoS biology.

[24]  P. Nelson,et al.  Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. , 2003, Cancer cell.

[25]  D. Tindall,et al.  The role of PTEN in the progression and survival of prostate cancer. , 2003, Minerva endocrinologica.

[26]  C. Bucana,et al.  Adenoviral-mediated expression of MMAC/PTEN inhibits proliferation and metastasis of human prostate cancer cells. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[27]  F. Sarkar,et al.  Akt inactivation is a key event in indole-3-carbinol-induced apoptosis in PC-3 cells. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  D. Tindall,et al.  Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state. , 2001, Endocrinology.

[29]  R. Vessella,et al.  Increased AKT Activity Contributes to Prostate Cancer Progression by Dramatically Accelerating Prostate Tumor Growth and Diminishing p27Kip1 Expression* , 2000, The Journal of Biological Chemistry.

[30]  T. Mak,et al.  High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten+/- mice. , 2000, Cancer research.

[31]  C. Cordon-Cardo,et al.  Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[32]  C. Sawyers,et al.  The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[33]  Carlos Cordon-Cardo,et al.  Pten is essential for embryonic development and tumour suppression , 1998, Nature Genetics.

[34]  R. Vessella,et al.  Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[35]  S. Keam,et al.  Spotlight on Bicalutamide 150mg in the Treatment of Locally Advanced Prostate Cancer , 2007, Drugs & aging.

[36]  M. Resnick,et al.  Constitutive activation of P I3 K-Akt and NF-kappaB during prostate cancer progression in autochthonous transgenic mouse model. , 2005, The Prostate.